Jump to content
Please ensure regular participation (posting/engagement) to maintain your account. ×
The Bangladesh Defence Analyst Forum

Bangladesh's Pharmaceutical Industry

Recommended Posts

  • Elite Members

12:00 AM, July 13, 2020 / LAST MODIFIED: 03:14 AM, July 13, 2020

Pharma companies count their blessings as exports rise

Jagaran Chakma


Bangladesh's pharmaceutical industry managed to grow its exports in the just-concluded fiscal year on the back of a steady demand for medicines during the coronavirus-induced economic and health crises, which have decimated other major export sectors.

"Pharmaceutical products are essential for all countries. That is why the industry's exports did not decline amid the Covid-19 outbreak. Rather, it rose," said Ananta Saha, international business manager of Renata.

Pharmaceutical shipments soared 4.49 per cent year-on-year to $136 million in fiscal 2019-20 following improvements in product quality and policy support.

The industry is one of the handful of sectors that ended the fiscal year in the black. National exports fell 16.93 per cent.

The sector fetched $130 million in export earnings in fiscal 2018-19 and $103.46 million in fiscal 2017-18.

One of the major manufacturers and exporters, Renata ships products to 27 countries and sells nutrition products in bulk quantity to the Unicef for distribution in African countries.

"Although we were unable to approach our clients personally, buyers supported us by communicating online to place fresh orders," Saha said.

Renata achieved its export target for the just-concluded fiscal year.

The pandemic prompted medicine-makers to introduce digital marketing as a new avenue for sales. However, it is difficult to gauge future market demand for pharmaceuticals since all fairs and seminars related to the industry have been put on hold or cancelled to prevent mass infections, Saha said.

Bangladesh is currently exporting medicines to many countries across four continents, including a few highly regulated markets in the European Union and Australia, said Mohammad Mujahidul Islam, director for marketing and sales at Eskayef Bangladesh, another pharmaceuticals company.


Numerous regulatory bodies -- the European Union Good Manufacturing Practice, the Medicines and Healthcare Products Regulatory Agency of the UK, the Therapeutic Goods Administration of Australia, the United Arab Emirates Good Manufacturing Practice and the Veterinary Medicines Directorate of the UK -- approved Eskayef's state-of-the-art manufacturing facility.

"This only reinforced the company's high standards for quality, safety and efficacy. For this reason, Eskayef's exports have increased," he said.

Although the country's export earnings from the sector are still comparatively insignificant, it has good potential in the global market. The domestic pharmaceuticals market is dominated by six major players.

Square Pharmaceuticals leads the pack with an 18.8 per cent market share, while Incepta comes in second with 10.2 per cent.

Beximco is in the third position with 8.5 per cent share, followed by Opsonin 5.6 per cent, Renata 5.1 per cent and Eskayef 4.5 per cent, data from the Bangladesh Association of Pharmaceutical Industries showed.

Sanofi and Novo Nordisk also have a notable presence in the segment for specialised products.

Bangladesh ships pharmaceutical products to 144 countries after meeting 98 per cent demand of the growing domestic market.

"Foreign buyers are constantly visiting our factories to examine production quality and more often than not, they place orders before leaving," said Saha.

Monjurul Alam, director for global business development at Beacon Pharmaceuticals, said that the company exports its products to 141 countries, including some in the EU.

Demand has increased after Bangladesh's pharmaceutical industry became capable of producing advanced medicine such as bio-similar drugs, vaccines and oncology products as well as various medical apparatuses.

Beacon ships oncology products to Sri Lanka, Nepal, Myanmar, Singapore, Malaysia and a few African nations, Alam said.

"However, export volumes are still low. So, we should grab the regulated market to increase shipment sizes," he added.

Alam estimates that the sector has a domestic market value of about Tk 22,000 crore.

In 2012, the local market size stood at around Tk 9,390 crore. By 2017, it doubled to Tk 18,755 crore, according to a report of the IMS Health Care.

Prof Syed Modasser Ali, chairman of the Bangladesh Medical Research Council, said the pharmaceutical sector has huge potential for exports as local companies are rapidly adopting sophisticated technologies to ensure quality products.

"The export of Bangladeshi medicine would increase more if the commerce, finance, and foreign affairs ministries cooperate proactively to expand its presence in the global market," he said.

The economic or commercial councillors of Bangladesh embassies abroad should contribute in this regard, the former health adviser to the prime minister said.

Local medicine consumption is increasing in line with the country's economic growth and growing awareness of treatments, he added.

With a compound annual growth rate of 15.6 per cent, the sector is predicted to grow to $5.11 billion by 2023, according to LightCastle Partners.



Link to comment
Share on other sites

  • 3 weeks later...

Remdesivir saved the day for pharma industry

Beximco that made the remdesivir first in the country has already exported around 50,000 vials that worth nearly $3 million to at least six countries


Over the four decades of its journey, Bangladesh's pharmaceutical sector has evolved as a strong industry that is capable of meeting 98 percent of local demand that amounted to around $3 billion in 2019.

Bangladesh is now the only least-developed country among 47 nations that has a well-developed pharmaceutical sector that can produce medicines for cancer diseases and biological products such as insulin and vaccines.

The country is also doing well in exports in recent years and exported medicines worth $136 million to 151 countries in the just-concluded fiscal year.

The ongoing Covid-19 pandemic has opened up a new window of opportunity for local drug makers as the demand for antiviral drug remdesivir is increasing worldwide in the absence of a vaccine or other drugs that can effectively treat Covid-19 patients.

"We have permitted six companies for the export," said Ayub Hossain, spokesman at the Directorate of Drug Administration that regulates the drug makers in Bangladesh.

In early May, the Directorate General of Drug Administration gave permission to six pharmaceutical companies to produce remdesivir, a potential Covid-19 drug.

The companies are Beximco, Beacon, Eskayef (SK-F), Incepta, Square and Healthcare. However, Beximco produced the drug first in the country. It has a history to work well against the SARS and Ebola virus.

Three among these six companies have already begun exporting the drug, which is being used on Covid-19 patients in several countries, including the United States.

Beximco has already exported the medicine to at least to six countries – Azerbaijan, Pakistan, Nigeria, the Philippines, Venezuela and Lebanon.

"We are getting export queries from many countries. But our priority is to serve the needs of the local market," said Rabbur Reza, chief operating officer at Beximco Pharma.

Reza said they have so far exported around 50,000 units (vials) of Bemsivir (remdesivir).

Beximco is trying to export remdesivir to around 30 countries, he added.

Currently, Beximco is capable of producing 80,000 vials of Bemsivir per month, which the company wants to double by next month, he said.

Eskayef has also exported the medicine to some countries and Beacon has got approval from the authorities to export it.

"We are going to sign a deal to export remdesivir to Iraq," said Ebadul Karim, managing director at Beacon Pharmaceuticals.

Karim also said they have received requests from a dozen countries from Asia, Latin America and Africa for its export.

"We are capable of exporting the drug after meeting the local demand," he said.

According to industry insiders, the export price for per vial remdesivir stands at $55 to $65, which is Tk5,500 (maximum retail price) in the local market. So, Beximco's export earnings would stand at around $3 million.

However, local drug makers cannot go for a blanket export as they have to take prior approval for the export of remdesivir. But such permission is not mandatory for the export of favipiravir, another medicine being used to treat Covid-19 patients in some countries.

Market players said Bangladeshi companies are increasingly getting known to the world for its medicine, which will ultimately help them boost export.

To boost exports, local drug makers are conducting clinical studies for more and more products so that their exports become easy.

Clinical trials are the primary way by which researchers find out if a new drug is safe and effective in human body.

Various companies in the country are now conducting clinical researches on around 300 products, mostly in the laboratories of foreign countries as Bangladesh does not have the capacity to do so.

Abdul Muktadir, chairman and managing director of Incepta Pharmaceuticals, said they are carrying out clinical research on around 30 products.

"But that is not enough. We need to do clinical research on more products if we want to boost exports," he said.

Reza of Beximco said they will set up a laboratory for carrying out clinical tests of medicine in one or two years.

The pharmaceutical market of Bangladesh has doubled once every five years since 2010. However, the novel coronavirus pandemic is now threatening to derail that spectacular achievement of the industry led by local players.

Back in 2010, the size of the pharmaceutical market was $852 million and it reached $1.64 billion after five years, according to the Bangladesh Association of Pharmaceutical Industries (BAPI), a forum of drug makers.

The market had grown to around $3 billion before the pandemic hit businesses in April this year.

Research and Markets, a Dublin-headquartered firm, predicted in a report last week that Bangladesh's pharmaceutical industry will grow at an average of 12 percent per year for the next five years and take the market size to more than $6 billion by 2025.

The report said the majority of this growth would be contributed by local companies with a market share of more than 90 percent. The share of generic drugs will be over 85 percent in 2025 from around 75 percent now, it states.

Bangladeshi companies depend on imports to meet 95 percent of the raw materials. So, the country will be able to save foreign currency once the API Park starts functioning, industry players said.

Link to comment
Share on other sites

  • 1 month later...
  • Elite Members

12:00 AM, August 30, 2020 / LAST MODIFIED: 02:05 AM, August 30, 2020

Australian biotech firm to set API plant at BSMSN for $30m

Jagaran Chakma


Australian biotechnology company HA TECH will invest up to $80 million, or roughly Tk 700 crore, to establish a large-scale active pharmaceutical ingredient (API) manufacturing facility in Bangladesh that could help the country meet its growing demand.

"We aim to fulfil the demand for quality APIs in Bangladesh," Abdullah Al Mahmud, executive chairman of HA TECH, told The Daily Star.

Initially, the Sydney-based company, which produces APIs mainly for cardiovascular, diabetic, ulcer and oncology applications, will invest $30 million to develop the facility.

But within the next five years, the total investment could reach $80 million if the company wants to increase the product range.

There are about 10 local companies, including Eskayef, Square, Beacon and Beximco, that produce API materials on a limited scale, according to SM Shafiuzzaman, secretary general of Bangladesh Association of Pharmaceutical Industries (BAPI), a collective of about 250 local drug markers.

Local production can at best meet 5 or 6 per cent of the annual demand from the pharmaceutical sector, which has only grown in stature with the onset of the coronavirus pandemic, according to Monjurul Alam, director for global business development at Beacon Pharmaceuticals.

Subsequently, Bangladesh spends about $1.3 billion each year to import APIs from the US, Taiwan, Italy, Germany, Spain, Switzerland, France and the UK.

Development works for HA TECH's upcoming state-of-the-art good manufacturing practice (GMP) facility spanning 10 acres on at the Bangabandhu Sheikh Mujib Shilpa Nagar (BSMSN) will begin in January, said Paban Chowdhury, executive chairman of the Bangladesh Economic Zones Authority (BEZA).

HA TECH and BEZA signed the land lease agreement on 25 August.

The facility is expected to go into full operation by sometime next year.

Securing more foreign direct investment (FDI) for the country's Tk 22,000 crore-pharmaceutical industry, particularly API manufacturing, is crucial for propping up the sector, Chowdhury said.

About 98 per cent of the annual domestic demand for pharmaceutical products is met by BAPI members. After meeting the local demand, the products are shipped to 144 different countries.

Pharmaceutical shipments rose 4.5 per cent year-on-year to $136 million in fiscal 2019-20 following improvements in product quality and policy support.

The National Board of Revenue recently declared that imports of API products, pharmaceutical raw materials and reagents would be exempt of VAT until 2025 in a bid to boost the sector.

However, the tax authority also imposed a condition on API producers that require them to spend at least 1 per cent of their annual turnover on research and development projects for them to avail the benefit. The minimum value-addition should be 60 per cent.

"Our pharmaceutical sector will contribute to export diversification. Therefore, BEZA always welcomes API manufacturers at economic zones and is ready to roll out the red carpet, if needed," he added.

There is a huge potential to invest in API manufacturing in Bangladesh, said Beacon Pharma's Alam.

The reason being, the pharmaceutical sector is expected to grow 15 per cent year-on-year to reach $5.1 billion by 2023, propelled by investments from local companies that seek to grab a bigger share of the global market, according to an estimate.

Mahmud though is buoyant that HA TECH's facility will become a manufacturing hub for a range of finished pharmaceutical products as well. This includes nucleic acid drugs that use oligonucleotide, which is one of the newest segments of innovative medicine.



Link to comment
Share on other sites

  • 1 month later...
  • Elite Members

08:10 PM, October 21, 2020 / LAST MODIFIED: 08:12 PM, October 21, 2020

Ambassador of Brazil lauds Eskayef Pharmaceuticals’ world-class standards

Star Online Report


Photo: Collected

The Ambassador of Brazil to Bangladesh, Joao Tabajara de Oliveira Junior, visited the state-of-the-art manufacturing facility of Eskayef Pharmaceuticals Limited at Tongi today.

The ambassador was welcomed by Simeen Rahman, Group CEO of Transcom Limited and Managing Director and CEO of Eskayef Pharmaceuticals Ltd.

He visited various units of Faraaz Ayaaz Hossain Building where he was briefed about the world class technologies and operational excellence of the manufacturing facility, according to a press release.

During the visit, the ambassador was pleased to see the plant being established to the standards similar to that of the first world countries. He said, "The state-of-the-art manufacturing plant and its passionate professionals make Eskayef a world-class company here in Bangladesh. The pharmaceutical industry is one of the most promising export industries in Bangladesh. And Eskaeyf has all the potentials to export generic pharmaceutical products to Brazil and other countries of the world." Eskayef's initiative and far-sighted vision for COVID management, especially the launching of Remdesivir was highly appreciated by the Ambassador.

Simeen Rahman mentioned, "Bangladesh and the whole world is facing an unprecedented challenge due to the coronavirus pandemic. At Eskayef, we have a firm commitment to make every possible COVID-19 treatment available for the people of Bangladesh. We will serve the people to the best of our abilities in these crucial times."

She said, "Eskayef's core competency lies in manufacturing international standard sterile products. During the darkest time of coronavirus outbreak, when there was no effective drug to treat Covid patients, Eskayef launched Remdesivir injection which has not only served the patients of Bangladesh but also many countries of the world."

Eskayef's manufacturing facility is approved by many global and stringent regulatory authorities including UK MHRA, EU GMP and TGA Australia.

Eskayef has recently become one of a few Asian companies to secure approval from the prestigious regulatory body European Union Good Manufacturing Practice (EU GMP) to produce anti-cancer drugs. Oncology Manufacturing Facility of Eskayef Pharmaceuticals is the country's first entity that has secured approval from the EU GMP.

Eskayef has been manufacturing quality medicines for the past 30 years. After serving the patients of Bangladesh, the company is exporting its products to 54 countries across Europe, North America, South America, Australia, Africa and Asia.





Link to comment
Share on other sites

  • 4 weeks later...
  • Elite Members

12:00 AM, November 16, 2020 / LAST MODIFIED: 03:48 AM, November 16, 2020

Bangladesh on track to becoming a $6b pharma market by 2025

Says Irish market research firm

Jagaran Chakma

The pharmaceutical market of Bangladesh is expected to surpass $6 billion by 2025 with an absolute growth of 114 per cent from its 2019 levels, according to a report from a Dublin-based market insight and analysis firm, Research and Markets.

"The pharmaceutical market has been witnessing excellent growth in recent years, and it is expected to have a compound annual growth rate of more than 12 per cent during the 2019-2025 period," said the report titled "Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025".

According to the report, biotech pioneers of Bangladesh's pharmaceutical industry are considered as a valuable tool for the overall improvement and efficacy of the market.

A majority of the growth will be contributed by local companies with a market share of more than 90 per cent as similar to past trends attained over the last two decades, the report said.

In recent times, local pharmaceutical companies have emerged as a game-changer by contributing more than 90 per cent of the overall available medicines in the market.

Market players estimate that the local market size of the sector was about Tk 25,000 crore ($3 billion) in 2019. In 2012, it stood at about Tk 9,390 and in 2017 it hit Tk 18,755.6 crore, according to the IMS Health Care Report.

The pharmaceutical industry, a winner of the global market through dynamism and technology, experienced tremendous growth in the last decade and currently contributes 1.83 per cent to the country's gross domestic product (GDP), according to industry people.

Local pharmaceutical makers still have immense potential in the healthcare sector, as Bangladeshis spend around $2.04 billion abroad annually for medical treatment, which is 1.94 per cent of the country's GDP, according to a market analysis by the Bangladesh Investment Development Authority (Bida).

The demand for healthcare services is growing at about 21 per cent annually thanks to the increasing purchasing power of the growing middle and upper-middle classes, the Bida said.

The notable change that attracted the world towards Bangladesh is a consequence of innovation in the science and research and development sector, the Research and Markets said in its report.

Rise in life expectancy, growing per capita income, changing disease profile, population growth, lifestyle changes and increasing patient population are some of the key drivers that are boosting consumption in the local market, it said.

In the upcoming years, the government of Bangladesh will play a significant role in the rapid growth of the pharmaceutical market by providing favourable policies for easy drug approval, production and marketing of new products, the Irish firm expects.

The government is focusing on reducing the country's dependence on the import of raw materials. The establishment of an API Park will act as a turning point for this purpose.

The top 50 companies are setting up their facilities at the Active Pharmaceuticals Ingredient Industrial Park in Munshiganj that will help in the production of patented and already opened active pharmaceuticals ingredients.

It is expected that the development of the API Park will be complete by the next two years, which will reduce the expenditure related to the import of raw materials.

The report said the share of generic drugs is expected to surpass 85 per cent by 2025, which will further strengthen the dominance of local pharmaceutical companies in the market.

"The capacities of local companies are improving, and they are expanding their facilities and investing in research and development, which will help the sector grow," said SM Shafiuzzaman, secretary-general of the Bangladesh Association of Pharmaceutical Industries (BAPI), a platform of about 250 local drug-markers.

He also said the availability of workforce is also an essential factor for the sector to flourish.

There is no difference in quality between original products and the generic products manufactured in Bangladesh, he said. "Bangladeshi pharmaceutical products have always maintained global standards."

"The quality and global image of Bangladesh's medicines are better than the generics produced in India and Egypt," said Monjurul Alam, Beacon's director for global business.

"Since our labour cost and utilities are cheaper than in many countries, our products are more affordable compared to other medicine manufacturing nations."

The general people of Bangladesh can now afford medicines as their purchasing power has increased four times in the last 20 years, he said.

"Moreover, people are well aware of diseases now. Chronic diseases are increasing, which need a regular intake of medicines. All these have triggered the domestic market to boom."

Moreover, local companies are investing and developing dedicated facilities for specialised drugs for treating diseases such as cancer, he said.

"At least 10 to 15 facilities are producing products of international standards. We are now working on producing APIs. If we can start the API production, we can offer more advanced drugs at a more affordable price."

The pharmaceutical industry has managed to grow its exports in the current fiscal on the back of steady demand for medicine amid the coronavirus-induced economic and health crises, which have decimated other major export sectors.

"Pharmaceutical products are essential for all countries. That is why the industry's exports did not decline amid the Covid-19 outbreak. Rather, it rose."

Pharmaceutical shipments soared 4.49 per cent year-on-year to $136 million in fiscal 2019-20 following improvements in product quality and policy support.

The industry is one of the handful of sectors that ended the fiscal year in the black when national exports fell 16.93 per cent.

The sector fetched $130 million in export earnings in fiscal 2018-19 and $103.46 million in fiscal 2017-18.

"As a least developed country, Bangladesh does not need to follow the patent, making it easy to formulate any generic drug locally," said Ananta Saha, international business manager of Renata.

He said the population of Bangladesh is large, which is one of the main reasons for the local pharmaceutical industry's rapid growth.

Regarding the export forecast, he said it would be achievable as it is easy to export pharma products from an LDC to another.

The efficiency of the local companies is improving, and they are expanding their manufacturing facilities, said Muhammad Halimuzzaman, deputy managing director and chief executive officer of Healthcare Pharmaceuticals.

Rabbur Reza, chief operating officer of the company, believes Bangladesh would be able to reach the export target for 2025 if the local sector continues to grow at the current rate.

However, he said Bangladesh has to wait until June next year to find out the pharmaceutical industry's accurate growth rate, which will indicate whether the industry will be able to reach the $6 billion target by 2025.

The economic growth of the country is helping the sector grow faster, he said.

The rising purchasing power of the people and awareness about the treatment is working as a driving force for the sector, he added.



Link to comment
Share on other sites

Production of API is a much needed one. Because  "It’s of some concern, then, that if Bangladesh potentially leaves the LDC category in 2024 it’ll no longer have access to a special World Trade Organisation (WTO) waiver which exempts the industry from the Agreement on Trade-Related Aspects of International Property Rights (TRIPS). The exemption has allowed government to pursue a dedicated industrial policy that’s spurred growth until now." https://www.un.org/ldcportal/what-ldc-graduation-will-mean-for-bangladeshs-drugs-industry/ 


Link to comment
Share on other sites

  • 7 months later...
  • 1 month later...
  • Elite Members


Abbas Uddin Noyon

07 August, 2021, 10:40 pm

Last modified: 08 August, 2021, 11:08 am

Pharmas eye strong local base for key ingredients

Some companies hope to start production at API park next year



The pharmaceutical industry of the country is going to make a giant stride as local companies are setting up factories in a dedicated park near Dhaka to produce active pharmaceutical ingredients (APIs) to reduce dependence on import for key raw materials for drugs.

At least five companies including Acme, Healthcare, UniHealth and Ibn Sina have started setting up factories in Munshiganj's Gazaria API Park and a dozen more companies including Square, Beximco, and Opsonin are going to do the same soon. Some of the companies said they would start production from the beginning of next year.

API Industrial Park Project Director Syed Shahidul Islam told The Business Standard that 27 companies have taken allotment of plots with an expected investment of Tk3,000 crore. Acme and Healthcare have made considerable progress on their API facilities and they plan to start production in 2022.

Creation of specialised zones, 10-year tax holiday offer and formation of a national API policy are among the supports the industry finds encouraging for local production of key drug ingredients.  

Experts say that the innovative production of API by the local pharmas would help keep this booming Tk27,000 crore sector on track in future.

According to the Bangladesh Association of Pharmaceutical Industries (Bapi), at present, local companies can produce only 3% of the total demand for central ingredients of drugs and import the remaining 97% from various countries.

Active pharmaceutical ingredients (API) are the main components of medicines. Inventors of such ingredients usually patent them to retain intellectual property rights. Any drug manufacturer that wants to produce medicines using that API must pay a royalty fee to the inventor.

Bangladesh does not have to pay any royalty or fee for the use of foreign patents in medicine production as the World Trade Organisation's Trade Intellectual Property (TRIPS) Agreement gives the country the right to do so as a least developed nation.

Experts say that after five years, when Bangladesh leaves the LDC title in 2026, the TRIPS facility will no longer be applicable. As a result, the pharmaceutical industry of Bangladesh will enter a new phase of paying royalties or fees for patents that will increase the cost of medicines.

However, sector insiders are hopeful that the country will go for innovation in medicine ingredients before that.

SM Shafiuzzaman, secretary general of Bapi, said, "We are moving towards becoming self-sufficient in raw material production. One or two factories will be able to start production in the industrial park from next year. By 2030, all the factories there will be able to go into API production."

Infrastructures completed by the government

The decision of the API Industrial Park was taken in 2008 to expand the domestic pharmaceutical industry, diversify products to create a competitive market, conduct research on improving the quality of medicines and produce the required raw materials. The Executive Committee of the National Economic Council (Ecnec) approved the project in December of the same year.

The government has already completed the construction of the 200-acre project in Munshiganj's Gazaria including plot development, land filling, roads, drainage system, electricity and water lines etc.

Twenty-seven companies including big names like Square, Beximco, Incepta and Acme have already made places there. A company can take a maximum of 10 acres and a minimum of 5 acres of land. Several companies have already started construction of buildings. The government has initially decided to charge Tk2 crore per acre of land.

Project Director Shahidul Islam said, "Work on a section of the Central Waste Treatment Plant (CEPT) would be completed by this year. Companies will be able to start production from next January."

The preparation of the companies

Acme Laboratories Limited is at the forefront of setting up factories in API Industrial Park. The company has already completed the construction of the fourth floor of their building at a cost of Tk60 crore. The company hopes to start production in June 2022.

Mizanur Rahman Sinha, managing director of ACME Laboratories Ltd, said, "The construction of our building will be completed by December this year. It will take some more time to complete other preparations including capital machinery. However, we will be able to start production in June 2022."

Besides, Healthcare, UniHealth, Ibn Sina Pharmaceuticals have started construction of buildings in the industrial park.

Square Pharma, the country's leading pharmaceutical company, is conducting a feasibility study to set up a factory in the industrial park where they have three plots. They will start construction of their building there early next year.

Zahangir Alam, CFO of Square Pharmaceutical Ltd, said, "We have completed the initial feasibility study to invest in the API. Our construction work will start there soon. However, being a listed company in the capital market, we cannot disclose our investment."

Another top company Opsonin Pharma has taken two plots in the park. The company is also planning to invest from the beginning of next year.

Abdur Rouf Khan, managing director of Opsonin Pharmaceutical Ltd, said, "We put utmost importance on API production. However, as the company's existing factory renovation work is underway, we are not able to invest in API Park right now. We will do it next year."

Like Square and Opsonin, almost all companies, including Beximco, are planning to set up factories next year.

Syed Shahidul Islam, project director of the API, said, "The construction work of the factories of Healthcare and ACI Limited has progressed considerably. Next year almost everyone will start working on their factories."

Tax holiday facility in API production

The National Board of Revenue (NBR) has allowed a 10-year tax holiday to the API Industrial Park for setting up factories to produce medicine raw materials. This facility is being provided in the light of the National Active Pharmaceutical Ingredients (API) policy.

A company will get this facility for 10 years after starting production. Under this, the producers of raw materials in the pharmaceutical industry will enjoy 100% corporate tax exemption and other tax benefits.

Pharmaceutical industry market

The pharmaceutical industry has developed considerably in Bangladesh. In the post-independence period, Bangladesh was almost 100% dependent on foreign medicines. But now Bangladeshi medicines are even being exported to 180 countries of the world.

Local companies are now meeting 98% of the demands of the domestic market. They are now developing and producing a variety of complex and international standard medicines including vaccines, medicines for heart and cancer diseases and insulin.

According to IQVIA, an American multinational company serving the pharma industry, the country's pharmaceutical market has surpassed Tk27,000 crore in 2020 with an annual growth of more than 10%. Bangladeshi companies also export medicines worth around Tk1500 crore per year. However, the top 10 companies in the country sell about 71% of the country's total medicines.

According to the Export Promotion Bureau, the revenue from drug exports in the 2020-21 fiscal year was Tk1,433 crore. In that year, the income growth in this sector was 24.50%. In 2019-20, medicines worth Tk1,153 crore were exported from Bangladesh.

Industries are expecting a brighter day for medicine export once the API is completed. But experts think API is not the only solution for patent rights.

Dr Khondaker Golam Moazzem, research director of the Centre for Policy Dialogue, said after setting up the API industrial park, innovation in generic medicine and patent rights should get importance. It needs foreign investment or joint ventures for new innovation in an API park.

Secondly, the Ministry of Commerce will have to negotiate to get the benefit of patent exemption until 2033, after LDC graduation in 2026.

Link to comment
Share on other sites

  • Elite Members


Omar Faruque

13 August, 2021, 09:00 am

Last modified: 13 August, 2021, 09:09 am

Chattogram’s Albion set to make drug export debut

Under the terms of the agreement, 20% of the payment for the first shipment reached Bangladesh on 9 June



Albion Laboratories Limited in Chattogram is on its way to becoming a new exporter in the pharmaceutical sector. Albion Group's affiliate has been waiting for the export of drugs worth $66,690. The first shipment from Chattogram port to Kabul, Afghanistan, will reach its destination next month.

The company obtained the good manufacturing practice (GMP) certificate on 13 January this year. Then on 29 May, there was a confirmation about the export.

Under the terms of the agreement, 20% of the payment for the first shipment reached Bangladesh on 9 June.

In addition to Afghanistan, invoices have been issued for export of 10 pharmaceutical products worth $53,650 to Yemen, which will open a drug export bond from Albion next week.

The Albion authorities are preparing for the shipment of drugs from Chattogram port to Aden in Yemen in the first week of October.

Albion Laboratories is on the verge of exporting drugs to Cambodia, Myanmar and Bhutan. The three countries are currently in the process of getting approval from their health ministries.

The drugs produced by Albion will have generic names as well as brand names abroad. The company has been producing various types of complex medicines of an international standard, such as tablets, capsules and injections. That is why Albion is gradually increasing its investment in Sitakunda.

There are a variety of antibiotics among nearly 450 human health-related drug items. Additionally, there are new products, among which are one-time injection syringes, drops and injectable items.

According to the Bangladesh Export Promotion Bureau (EPB), in fiscal 2020-21, medicines worth $169 million or Tk1,436 crore were exported from Bangladesh to 123 countries around the globe. The highest volume of these exports went to neighbouring Myanmar.

In the last fiscal year, the export of medicines to Myanmar amounted to $18.21 million. Sri Lanka was next with $15.76 million in exports.

According to the Directorate General of Drug Administration, Bangladesh's share of the Sri Lankan drug market is 7.4%. And 4.53% of the Myanmar drug market is dominated by Bangladeshi items.

The company has also prepared a table for the second and third steps by reviewing data related to the importing countries in the process of exporting drugs. The list includes Sri Lanka, Vietnam and the Philippines. The next step will be the African countries of Sudan, Ghana, Somalia, Cameroon and Nigeria.

Kuala Lumpur is also interested in reducing China's dominance in the Malaysian pharmaceutical market. For this reason, Albion sees the country as an important market. That is a reason why Albion's research team is analysing market entry data. Albion also has plans to expand its drug market in the West.

Raisul Uddin Saikat, chairman of the Albion Group, said, "It is a great pleasure for us to be able to start our journey as the first Chattogram-based drug exporter. But, as it is a competitive market, the profit margin on exports is very low."


Md.Raisul Uddin Saikat, Chairman of Albion Laboratories Ltd

He said the Bangladesh government wants to increase the spread of Bangladeshi medicines abroad. As a way of promoting the policy, a 10% incentive has been given by the government to encourage the export of medicines.

"We will also gradually open up our export market. Apart from that, it is also an honour to have the name of our organisation in the list of exports," he added.

Raisul Uddin Saikat said the Albion Group has approval to produce 450 types of drugs. Of these, Albion is currently marketing 300 varieties.

"Lotil-20, Monkon-10, Reclevus Met, Epram and Olme-20 of the omeprazole group are among the top drugs produced by Albion," he added.

Officials at Albion Laboratories say it has not been easy to get nominated or recognised for exports to multiple countries. Manufacturing activities have been in line with the World Health Organization (WHO) defined GMP.

Albion medicines are now ready to go to different countries after passing the appropriate quality verification tests and gaining some significant certificates in the global pharmaceutical sector. As it is a sensitive product, it is as difficult and time consuming for an importer to get a country clearance, they added.

In 1991, Albion Laboratories Limited started production of 15 categories of drugs on a small scale with 100 employees. The company started production in a rented building in Chandgaon residential area of Chattogram. And this beginning was in the hands of Md Nezam Uddin. As managing director of the company, he also had a seat in business management.

The second generation, meaning the children of Nezam Uddin, has been involved in the business since 2006. Nezam Uddin's elder son Raisul Uddin Saikat studied computer science in Australia.

After completing his studies, he quickly returned to the country and joined Albion Laboratories Limited as an officer. The business style of the company keeps changing with new plans. Self-identification in exports is one of the most significant changes in the work of the firm.

Raisul Uddin Saikat is currently chairman of Albion Group. Muntahar Uddin Sakib, the second son of Nezam Uddin, joined the company in 2012 after completing his studies as a chartered accountant in Malaysia. He is currently serving as managing director. Daughter Tasnuva Afrin, a pharmacist, is currently serving as a director of the company.

The production of medicines started in 2007 in Barbakunda of Sitakunda upazila in Chattogram on an area of 50,000 square feet. The scope is now being extended to meet the needs of expanding infrastructure facilities in light of the drug export plan being undertaken. The Albion Group has started operating drug production activities on an area of 140,000 square feet. The factory, with 100 people, is now going to provide direct employment to 3,000 people at Albion Specialised Pharma Limited.

Link to comment
Share on other sites

  • Elite Members


Bangavax animal trials begin

 JUBAIR HASAN | Published:  August 18, 2021 08:38:04 | Updated:  August 18, 2021 11:49:52


After months of uncertainty, Globe Biotech Limited (GBL) restarted preclinical or animal trials of its homegrown Covid vaccine, Bangavax, in a breakthrough.

This time, it is being trialed on monkeys to meet the condition set by Bangladesh Medical Research Council (BMRC), the authority that gives approval for clinical or human trials of any antidote here.

The company, GBL, earlier in October last year, had announced that its mRNA vaccine showed promise in animal trials on mice. Based on the successful trials, company officials said, the local drug firm had approached the BMRC for ethical clearance before the human trials.

But the council approved clinical trials of Bangavax under the condition that "before starting any human trial, the vaccine producer requires to conduct an animal trial on monkeys or chimpanzees.

"We started animal trials of Bangavax on monkeys on August 1st in line with BMRC's condition," senior manager (quality and regulatory operations) of Globe Biotech Limited Dr Mohammad Mohiuddin said.

Citing revised plan of the GBL, he said the pre-clinical trials are expected to be completed within next month and the company planned to conduct human trials from November.

Responding to a question, he said they tried to conduct trials on monkeys overseas. India asked them to move ahead with the G2G (government to government) mechanism but did not get expected response from the department concerned even after repeated approach.

He said Bangavax is a new-generation mRNA vaccine like the Pfizer and Moderna ones. Developed countries say monkey trials of mRNA-type vaccines are not necessary but BMRC makes it mandatory.

"So, we are forced to conduct the monkey trials after getting permission from the forest department maintaining international standards," he added.

Talking to the FE, BMRC director Prof Dr Ruhul Amin said they would provide all kinds of corporation to the Bangavax authority once the monkey trials are done.

"I know conducting animal trials again will take time, but we have nothing to do. This is a major requirement that needs to be fulfilled," he added.

The lone coronavirus-vaccine candidate of the country sought ethical approval from the BMRC for human trials of the antidotes on January 17 last.

The BMRC on February 09 asked for some documents and the company delivered those on February 17. After four months of silence, the BMRC in June last gave the conditional approval.

Expressing dissatisfaction over the dilemmas, healthcare experts feared that Bangavax might face the same fate as the rapid-test kit developed by Gonoshasthaya Kendra.

"I don't understand why the BMRC did not notify the GBL about the money factor when the vaccine developer first approached them. Why is it delayed needs to be cleared," BMA secretary-general Dr Md. Ehteshamul Huq Choudhury said.

Link to comment
Share on other sites

  • Elite Members


Ambee Pharmaceuticals’ Q3 earnings plunges

 Tribune Desk

 Published at 04:59 pm August 18th, 2021



The closing price for each of its shares was Tk454.1 during Wednesday’s trade

The third quarterly (January-March) earnings of Ambee Pharmaceuticals Ltd plunged by 60%. 

In a filing with Dhaka Stock Exchange on Wednesday, the company said that its earnings per share (EPS) was Tk0.30 for the Q3 of 2021 as against Tk0.75 for the same period of the previous financial year. 

Meanwhile, its net asset value (NAV) per share was Tk23.25 as of March 31, 2021, and Tk24.10 as of June 30, 2020.

Back in the year 2020, Ambee Pharmaceuticals offered a 15% cash dividend to its shareholders. The closing price for each of its shares was Tk454.1 during Wednesday’s trade.

Link to comment
Share on other sites

  • 3 weeks later...
  • Elite Members


TBS Report

02 September, 2021, 09:45 pm

Last modified: 02 September, 2021, 09:47 pm

BB allows Beximco to buy Sanofi shares at Tk480 crore

Beximco asks for Tk375 crore loans from Agrani Bank for the leveraged acquisition



The Bangladesh Bank has approved two foreign shareholders of Sanofi Bangladesh to sell their 54.6% stake in the multinational drug producing company at Tk480 crore.

The two UK-based companies -- Fisons Ltd and May and Baker -- are allowed to sell more than 19.63 lakh Sanofi shares at a rate of Tk2,445 each.

Beximco Pharmaceuticals Limited, a top local drugs maker is going to buy the entire stake and it applied for Tk375 crore in loans from state-owned Agrani Bank for the leveraged acquisition.

Beximco Pharma proposed to pay back the loan in five years, while the interest rate can go up to 9%, according to the bank's letter to the central bank seeking approval for the loan.

Link to comment
Share on other sites

  • 3 weeks later...
  • Elite Members


অ্যাসিডিটি অ্যান্টিবায়োটিক ডায়াবেটিস ওষুধ বাজারের প্রায় ২৫ শতাংশ

বদরুল আলম

সেপ্টেম্বর ২০, ২০২১


বছরে সাড়ে ১৮ শতাংশ হারে বাড়ছে দেশের ওষুধের বাজার। খাতসংশ্লিষ্টদের তথ্যমতে, ২০২০-২১ অর্থবছরে ২৭ হাজার কোটি টাকারও বেশি ওষুধ বিক্রি হয়েছে। ওষুধের এ বাজারের ৭১ শতাংশই নিয়ন্ত্রণ করছে ১০ কোম্পানি। আর যে ওষুধের ওপর ভর করে বাজার বড় হচ্ছে তার সর্বাগ্রে রয়েছে প্রোটন পাম্প ইনহিবিটরস বা অ্যাসিডিটির ওষুধ। সর্বাধিক বিক্রীত ওষুধের তালিকায় এর পরেই আছে অ্যান্টিবায়োটিক।

মোট বিক্রীত ওষুধের ১৩ দশমিক ১৫ শতাংশ অ্যাসিডিটির। অ্যান্টিবায়োটিকের ক্ষেত্রে এ হার ৬ দশমিক ৬৬ শতাংশ। অ্যাসিডিটি, অ্যান্টিবায়োটিকের পরই দেশে সবচেয়ে বেশি বিক্রি হয় ডায়াবেটিসের ওষুধ। ইনজেকশনের আকারে ব্যবহূত এ ওষুধের হিস্যা মোট বাজারের ৩ দশমিক ৬৩ শতাংশ। অর্থাৎ দেশের মোট বিক্রীত ওষুধের প্রায় ২৫ শতাংশই দখল করে আছে অ্যাসিডিটি, অ্যান্টিবায়োটিক ও ডায়াবেটিস।

স্বাস্থ্য বিশেষজ্ঞরা বলছেন, অনিয়ন্ত্রিত জীবনযাপন, ফাস্টফুড ও ভেজাল খাবার মানুষের মধ্যে অ্যাসিডিটি সমস্যা বাড়াচ্ছে। অ্যাসিডিটির ওষুধ বিক্রিও তাই সবচেয়ে বেশি। চিকিৎসকের ব্যবস্থাপত্র ছাড়াই ওষুধটি কিনতে পারাও এর বিক্রি বেশি হওয়ার আরেকটি কারণ। এদিকে সংক্রামক রোগ প্রতিরোধে ব্যবহূত হওয়া অ্যান্টিবায়োটিকের বিক্রি বাড়ার কারণ মূলত ক্রেতার অসচেতনতা। আর এক্ষেত্রে বিক্রেতাদেরও রয়েছে অতিমুনাফার প্রবণতা।

দেশে ওষুধ উৎপাদনকারী কোম্পানির ওষুধ বিক্রি ও ধরন নিয়ে জরিপ চালিয়েছে যুক্তরাষ্ট্রভিত্তিক স্বাস্থ্যসংক্রান্ত তথ্যপ্রযুক্তি ও ক্লিনিক্যাল গবেষণার বহুজাতিক প্রতিষ্ঠান আইকিউভিআইএ। তাদের প্রতিবেদন অনুযায়ী, ২০২০-২১ অর্থবছরে বাংলাদেশে ওষুধের বাজারের আকার দাঁড়িয়েছে ২৭ হাজার ৬৫৯ কোটি টাকায়। বাজারের বার্ষিক প্রবৃদ্ধি ১৮ দশমিক ৫৬ শতাংশ।

ওষুধের প্রকারভেদ বা থেরাপিউটিক ক্লাস বিবেচনায় ২০২০-২১ অর্থবছরে অ্যাসিডিটির ওষুধের বিক্রি ছিল ৩ হাজার ৬৩৫ কোটি টাকা। দেশের বাজারে এটাই সর্বাধিক বিক্রীত ওষুধ। গত বছর ওষুধটির বিক্রয় প্রবৃদ্ধি ছিল ১২ দশমিক ৩৬ শতাংশ। এ শ্রেণীর ওষুধ সবচেয়ে বেশি বিক্রি করেছে হেলথকেয়ার। সারজেল নামে এ ধরনের ওষুধ বিক্রি করছে হেলথকেয়ার। ম্যাক্সপ্রো নামে বিক্রি করছে রেনাটা। এ শ্রেণীর ওষুধ বিক্রয়ে হেলথকেয়ারের পরেই আছে রেনাটা, ইনসেপ্টা, স্কয়ার ও রেডিয়েন্ট। এ কোম্পানিগুলো অ্যাসিডিটির ওষুধ বিক্রি করছে ম্যাক্সপ্রো, প্যানটনিক্স, সেকলো ও এক্সিয়াম নামে।

গত বছর দ্বিতীয় সর্বাধিক বিক্রীত ওষুধ ছিল সেফালসফোরিন্স অ্যান্ড কম্বিনেশন, যা অ্যান্টিবায়োটিক। এ শ্রেণীর ১ হাজার ৮৪১ কোটি টাকার ওষুধ বিক্রি হয় গত বছর। ওষুধটির বিক্রয় প্রবৃদ্ধি ৭ দশমিক ৯৩ শতাংশ। অ্যান্টিবায়োটিক বিক্রির শীর্ষ প্রতিষ্ঠান স্কয়ার ফার্মাসিউটিক্যালস। সেফ-থ্রি ব্র্যান্ড নামে অ্যান্টিবায়োটিক বিক্রি করছে কোম্পানিটি।

বিশেষজ্ঞরা বলছেন, শুধু অ্যাসিডিটি বা অ্যান্টিবায়োটিকই নয়, সব ধরনের ওষুধ অপ্রয়োজনীয়ভাবে সেবন বেশি হচ্ছে। বিক্রির ক্ষেত্রে নিয়ন্ত্রণ না থাকা ও নিয়ন্ত্রক সংস্থাগুলোর তদারকির দুর্বলতার সুযোগে ওষুধের এমন প্রয়োগ বাড়ছে। রোগ প্রতিরোধ বা চিকিৎসার চেয়ে ওষুধের ওপর নির্ভরতা বাড়ছে মানুষের। এতে শরীরের রোগ প্রতিরোধক্ষমতা যেমন কমে যাচ্ছে, তেমনি তৈরি হচ্ছে নানা রোগের ঝুঁকিও। অ্যান্টিবায়োটিকের এমন অনিয়ন্ত্রিত ব্যবহার নিয়ে উদ্বেগ প্রকাশ করেছেন প্রধানমন্ত্রীও।

বাংলাদেশে আর্থসামাজিক প্রেক্ষাপট ওষুধের অনিয়ন্ত্রিত ব্যবহার বেড়ে যাওয়ার অন্যতম কারণ বলে মনে করেন বঙ্গবন্ধু শেখ মুজিব মেডিকেল বিশ্ববিদ্যালয়ের সাবেক উপাচার্য অধ্যাপক ডা. কামরুল হাসান খান। তিনি বণিক বার্তাকে বলেন, ‘আমাদের দেশে শিক্ষার হার আগের চেয়ে বেড়েছে। তবে প্রাত্যহিক জীবনের সঙ্গে এ শিক্ষার দূরত্ব রয়েছে। নিম্ন আয়ের মানুষ অসুস্থতা বোধ করলে চিকিৎসকের কাছে যায় না। তারা সহজেই ওষুধের দোকানে গিয়ে নিজের সমস্যার কথা বলে এবং ওষুধ নিয়ে আসে। এক্ষেত্রে তাদের অসচেতনতার পাশাপাশি বিক্রেতাদের অসাধু মনোভাব দায়ী।

ডা. কামরুল হাসান খান বলেন, ক্যান্সার থেকে শুরু করে চর্মরোগ—সব ধরনের রোগেই ওষুধের অনিয়ন্ত্রিত প্রয়োগ লক্ষণীয়। ফার্মেসিগুলোতে ফার্মাসিস্ট থাকার কথা, কিন্তু তা নেই। অ্যান্টিবায়োটিক দেয়া হয় মূলত সংক্রামক রোগ প্রতিরোধে। চিকিৎসকের ব্যবস্থাপত্র ছাড়া এসব ওষুধ বিক্রিতে বিধিনিষেধ রয়েছে। তবে দ্রুত আরোগ্য পাওয়ার উদ্দেশ্যে মানুষ সহজেই অ্যান্টিবায়োটিকের শরণাপন্ন হচ্ছে। কোনো বাধা ছাড়া তা কিনতেও পারছে তারা। এতে তাত্ক্ষণিক ফলাফল পেলেও দীর্ঘমেয়াদি জটিলতায় পড়তে হয়। ওষুধের এ ধরনের অনিয়ন্ত্রিত ব্যবহার বন্ধে আইনের প্রয়োগ নিশ্চিত করতে হবে।

দেশের বাজারে তৃতীয় সর্বোচ্চ বিক্রীত ওষুধ থেরাপিউটিক ক্লাস হিউম্যান ইনসুলিন। ডায়াবেটিকের ওষুধ হিসেবে পরিচিত এ শ্রেণীর ওষুধ গত বছর বিক্রি হয়েছে ১ হাজার ৩ কোটি টাকার। ওষুধটির বিক্রয় প্রবৃদ্ধি ছিল ১৫ দশমিক শূন্য ৭ শতাংশ। এ ওষুধ বিক্রির শীর্ষ প্রতিষ্ঠানগুলোর মধ্যে অন্যতম নভো নরডিস্ক ও ইনসেপ্টা।

হিউম্যান ইনসুলিনের পরেই গত বছর সর্বাধিক বিক্রীত ওষুধ থেরাপিউটিক ক্লাস ক্যালসিয়াম। হাড় ও অস্থিসন্ধির চিকিৎসায় ব্যবহার হয় এ শ্রেণীর ওষুধ। ২০২০-২১ অর্থবছরে এ ওষুধের বিক্রি ছিল ১ হাজার ২ কোটি টাকার। বিক্রির এ পরিমাণ ২০১৯-২০ অর্থবছরের তুলনায় ২২ দশমিক ৭৬ শতাংশ বেশি। গত বছর এ ওষুধ বিক্রয়কারী শীর্ষ তিন প্রতিষ্ঠান হলো স্কয়ার, রেডিয়েন্ট ও এসকায়েফ।

২০২০-২১ অর্থবছরে পঞ্চম সর্বোচ্চ বিক্রীত ওষুধ ছিল অ্যান্টিএপিলেপটিকস। স্নায়ুতন্ত্রজনিত রোগের এ ওষুধ বিক্রি হয়েছে ৯৬০ কোটি টাকার। বিক্রয় প্রবৃদ্ধি হয়েছে ২৬ দশমিক ৯১ শতাংশ।

শীর্ষ ১০ থেরাপিউটিক ক্লাসের মধ্যে ষষ্ঠ থেকে দশম অবস্থানে ছিল নন-নারকোটিক অ্যানালেসিকস, অ্যান্টিরিউমেটিক নন-স্টেরয়েড, ডিপিপি-আইবি ইনহিবিটর-ডায়াবস, অ্যানজায়োটেন-অ্যানট্যাগ ও অ্যান্টিলিউক অ্যান্টি-অ্যাজমাটিকস। গত বছর এ ওষুধগুলোর বিক্রয় প্রবৃদ্ধি ছিল যথাক্রমে ১৬ দশমিক ৮, ২৫ দশমিক ৩১, ১৫ দশমিক ৫৭, ২৫ দশমিক ৩৯ ও ৯ দশমিক ৭৪ শতাংশ।

আইকিউভিআইএর তথ্যমতে, বাংলাদেশের ওষুধের বাজারের ৭০ দশমিক ৬৯ শতাংশই নিয়ন্ত্রণ করছে স্কয়ার, ইনসেপ্টা, বেক্সিমকো, হেলথকেয়ার, রেনাটা, অপসোনিন, এসকায়েফ, অ্যারিস্টোফার্মা, ড্রাগ ইন্টারন্যাশনাল ও একমি। এর বাইরে শীর্ষ বিশে থাকা অন্য প্রতিষ্ঠানগুলোর মধ্যে আছে ড্রাগ ইন্টারন্যাশনাল, রেডিয়েন্ট, জেনারেল, ইউনাইমড অ্যান্ড ইউনিহেলথ, পপুলার, নভো নরডিস্ক, সানোফি বাংলাদেশ, ইবনে সিনা, বিকন ও নোভারটিস।

স্কয়ার ফার্মাসিউটিক্যালসের ব্যবস্থাপনা পরিচালক (এমডি) তপন চৌধুরী বণিক বার্তাকে বলেন, শুরু থেকেই স্কয়ার পণ্যের গুণগত মান ও গ্রাহকের আস্থার প্রতি সচেতন। এখন পর্যন্ত স্কয়ার এ মানসিকতার ধারাবাহিকতা রক্ষা করে চলেছে। ফলে আগামী দিনগুলোতে প্রবৃদ্ধি ধরে রাখার বিষয়ে আমরা আত্মবিশ্বাসী। স্কয়ার সেই কোম্পানি যারা বাজারের চাহিদার প্রতি তাত্ক্ষণিকভাবে সক্রিয় ভূমিকা নেয়। ওষুধের থেরাপিউটিক ক্লাসের সবই আমরা কভার করি ভোক্তার সুবিধার্থেই।

টানা তৃতীয় বছরের মতো সবচেয়ে বেশি বিক্রীত ১০ ওষুধের শীর্ষে রয়েছে হেলথকেয়ার ফার্মাসিউটিক্যালসের ব্র্যান্ড সারজেল। বছর তিনেক আগে ওষুধের সবচেয়ে জনপ্রিয় ব্র্যান্ড ছিল স্কয়ার ফার্মাসিউটিক্যালসের সেকলো।

ওষুধ শিল্প খাতসংশ্লিষ্টরা বলছেন, বিক্রিতে শীর্ষস্থানে পরিবর্তন ওষুধ পণ্যের লাইফ সাইকেলের স্বাভাবিক গতি। সেকলোর জেনেরিক নাম ওমিপ্রাজল। দেশে অনেক আগে থেকেই এ জেনেরিকের ওষুধ বাজারে আছে। তবে তুলনামূলক নতুন জেনেরিক ইসোমিপ্রাজল। এ জেনেরিকেরই একটি ওষুধের ব্র্যান্ড সারজেল। সাম্প্রতিক সময়ে চিকিৎসকের পছন্দ, ওষুধের কার্যকারিতাসহ নানা দিক বিবেচনায় ধীরে ধীরে গ্রহণযোগ্যতা কমছে ওমিপ্রাজলের। অন্যদিকে ব্যবহার বাড়ছে ইসোমিপ্রাজল, র্যাবেপ্রাজল ও লেন্সোপ্রাজল জেনেরিকের ওষুধের, চিকিৎসাবিজ্ঞানে যাকে বলা হয় ‘নতুন ভালো বিকল্পের সূচনা’। এ পরিবর্তনের প্রভাবেই জেনেরিক ইসোমিপ্রাজলের ব্র্যান্ড সারজেল বেশি বিক্রি হচ্ছে।

আইকিউভিআইএর তথ্য বলছে, ২০২০-২১ অর্থবছরে দেশের বাজারে সর্বাধিক বিক্রীত ওষুধের শীর্ষ ১০ ব্র্যান্ডে সারজেলের পরের অবস্থানগুলোতে রয়েছে যথাক্রমে রেনাটার ম্যাক্সপ্রো, ইনসেপ্টার প্যানটোনিক্স, স্কয়ারের সেকলো, রেডিয়েন্টের এক্সিয়াম, বেক্সিমকোর বাইজোরান, স্কয়ারের সেফ-থ্রি, একমির মোনাস, বেক্সিমকোর নাপা ও নাপা এক্সট্রা।

বিক্রীত ওষুধের শীর্ষ ব্র্যান্ডগুলোর মধ্যে শুধু গ্যাস্ট্রোনমিক্যাল ওষুধই রয়েছে পাঁচটি। প্যারাসিটামল গ্রুপের দুটি ব্র্যান্ড ছাড়াও অ্যান্টিবায়োটিক ও উচ্চরক্তচাপের ওষুধও রয়েছে এ তালিকায়। সবচেয়ে বেশি বিক্রীত ব্র্যান্ড সারজেলের বিক্রয় প্রবৃদ্ধি গত অর্থবছর ছিল ২৭ দশমিক ৫৬ শতাংশ। বিক্রি হয়েছে ৭১১ কোটি টাকার সারজেল।

হেলথকেয়ার ফার্মাসিউটিক্যালসের উপব্যবস্থাপনা পরিচালক ও সিইও মুহাম্মদ হালিমুজ্জামান বণিক বার্তাকে বলেন, বাংলাদেশের ওষুধের বাজারে উৎপাদিত পণ্য কমবেশি সব প্রতিষ্ঠানেরই এক। হেলথকেয়ার কোনো পণ্য প্রথম বাজারে নিয়ে এসেছে, এমনটা নয়। আমি মনে করি, হেলথকেয়ারের কর্মী বাহিনী তুলনামূলক বেশি উৎসাহ-উদ্দীপনা নিয়ে কাজ করছে বলেই আমাদের পণ্য বিক্রি বেড়েছে।

সারজেলের পর সবচেয়ে বেশি বিক্রীত ওষুধ ছিল রেনাটার ম্যাক্সপ্রো। গত অর্থবছর এ ওষুধ বিক্রি হয়েছে ৩৬৯ কোটি টাকার। বিক্রয় প্রবৃদ্ধি ছিল নেতিবাচক। ভ্যাকসিন উৎপাদনে বিখ্যাত হলেও গ্যাস্ট্রোনমিক্যাল ওষুধ বিক্রি বিবেচনায় তৃতীয় অবস্থানটি ইনসেপ্টা ফার্মাসিউটিক্যালসের প্যানটোনিক্স। গত অর্থবছরে ওষুধটি বিক্রি হয়েছে ৩৩৩ কোটি টাকার, প্রবৃদ্ধির হার ১৭ দশমিক ৮২ শতাংশ। ২০১৯-২০ অর্থবছরের তুলনায় ১০ দশমিক ৪৩ শতাংশ কমে সেকলো বিক্রি হয়েছে ৩৩০ কোটি টাকার। অবস্থান ছিল চতুর্থ। পঞ্চম অবস্থানে থাকা রেডিয়েন্টের এক্সিয়াম বিক্রি হয়েছে ২১৮ কোটি টাকার।

বিক্রির দিক থেকে ষষ্ঠ অবস্থানে রয়েছে বেক্সিমকোর বাইজোরান। গত অর্থবছর এ ওষুধ বিক্রির অর্থমূল্য ছিল ১৯০ কোটি টাকা, প্রবৃদ্ধি হয়েছে ২২ দশমিক ৩৬ শতাংশ। সপ্তম অবস্থানে থাকা ওষুধটি হলো স্কয়ারের অ্যান্টিবায়োটিক সেফ-থ্রি। ২০২০-২১ অর্থবছরে ওষুধটি বিক্রি হয়েছে ১৮১ কোটি টাকার। বিক্রয় প্রবৃদ্ধি ছিল ১০ দশমিক ৭৯ শতাংশ। অষ্টম, নবম ও দশম অবস্থানে থাকা সর্বোচ্চ বিক্রীত ওষুধ হলো যথাক্রমে মোনাস, নাপা ও নাপা এক্সট্রা।

স্বাস্থ্য বিশেষজ্ঞরা বলছেন, কোন ব্র্যান্ডের ওষুধ বেশি বিক্রি হচ্ছে, তা মানুষের শরীরে কার্যকারিতার পাশাপাশি ওষুধ কোম্পানির বিপণন কৌশলের ওপরও নির্ভর করে।

এ বিষয়ে স্যার সলিমুল্লাহ মেডিকেল কলেজ ও মিটফোর্ড হাসপাতালের গ্যাস্ট্রোএন্টারোলজি বিভাগের সাবেক বিভাগীয় প্রধান অধ্যাপক ডা. স্বপন চন্দ্র ধর বণিক বার্তাকে বলেন, গ্যাস্ট্রোনমিক্যাল ওষুধের বিক্রি বৈশ্বিকভাবেই বেশি। এর ব্যতিক্রম নয় বাংলাদেশও। দেশে প্রাপ্তবয়স্কদের মধ্যে প্রায় ৯০ শতাংশের অ্যাসিডিটির সমস্যা আছে। সে কারণে বাজারে অ্যাসিডিটির ওষুধের চাহিদা বেশি। সাম্প্রতিক সময়ে ওমিপ্রাজলের চেয়ে ইসোমিপ্রাজলের চাহিদা যেমন বাড়ছে, তেমনি চিকিৎসকরা র্যাবেপ্রাজল, লেন্সোপ্রাজল ব্যবহারের পরামর্শও দিচ্ছেন। ব্র্যান্ড যেটাই হোক সেটার পরিচিতি বা জনপ্রিয়তার পেছনে কোম্পানির বিপণন কৌশলও গুরুত্বপূর্ণ ভূমিকা রাখছে।

Link to comment
Share on other sites

  • 2 weeks later...
  • Elite Members


Jasim Uddin & Ahsan Habib Tuhin

04 October, 2021, 09:20 am

Last modified: 04 October, 2021, 09:26 am

Tax break till 2032 for API producers coming

To stay eligible for the tax break, raw material suppliers will also have to spend 1% of their annual turnover on research and development



The National Board of Revenue (NBR) is likely going to continue a tax break till 2032 for local pharma raw material producers, subject to complying with certain conditions, such as introducing at least five new ingredients a year.

The revenue board has come up with such a facility to achieve self-reliance on active pharmaceutical ingredients (API) and laboratory reagent and to draw in foreign investment, according to sources familiar with the matter.

According to Bangladesh Association of Pharmaceutical Industries, the country's pharma companies have a demand for around 6,000 crore worth of raw materials, which is growing by 12% per year. Domestic companies currently meet raw materials amounting to Tk400-500 crore.

According to law ministry sources, there is now a tax exemption in place on production of raw materials locally until 2022. The facility will now be extended to 2032 on certain conditions, as per a NBR proposal to the finance ministry.

Last week the law ministry gave its consent to the proposal, paving the way for the tax exemption, according to sources at the law ministry.

To stay eligible for the tax break, raw material suppliers will also have to spend 1% of their annual turnover on research and development.

Those who will manufacture three APIs or laboratory reagents will get a 22.5% cut in corporate tax, meaning that they will pay 7.5% in tax. Failing to conform to the conditions, non-listed companies will count a 30% regular corporate tax, while the listed ones will pay 22.5%, according to the NBR proposal.

If a company is penalised by any government regulatory authorities, such as the directorate general of drug administration, for manufacturing low-quality pharma raw materials in a given year, they will be stripped of the tax relief for that year.

A NBR letter sent to the finance ministry said domestic raw material production capacity will increase to Tk5,750 crore a year alongside creating around 5 lakh jobs if the new facilities are given to local manufacturers.

SM Saifur Rahman, managing director at Active Fine Chemicals Limited, told The Business Standard, "Bangladesh will not get the benefit of patent exemption under Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) from 2033. So, we will have to be self-sufficient in pharmaceutical raw material production."

In 2018, the commerce ministry formulated the National Active Pharmaceutical Ingredients and Laboratory Reagents Production and Export Policy to incentivise API production. The API policy aims to produce 370 key API molecules for exports and cut reliance on raw material imports by 2032.

As per the policy, API manufacturers are now enjoying the VAT exemption until 2032.   

Besides, the producers get a 20% cash incentive if they add a minimum 20% value. The conditions of value addition will be reviewed after 2026.

The APIs account for 30% of total drug costs in the case of small molecules and can go up to 55% for generic products. 

Currently, Bangladesh meets 98% of the demand for finished-form pharmaceutical products locally. Despite being nearly self-sufficient in the area of finished drugs, the country depends on imports for more than 90% of APIs. 

Heavy reliance on raw material imports makes the pharmaceutical industry vulnerable to supply chain disruptions and price volatility, according to industry insiders.

At present, 15 local companies, including Square Pharma, Beximco Pharma, Active Fine chemicals Ltd, ACI Limited, Globe Pharma, Gonoshasthaya Pharma, Opsonin Pharma, Drug International and Eskayef produce around 40 APIs. 

Among them, Active Fine chemicals Ltd is the only company listed on the capital market, which does not produce any finished medicine. Gonoshasthaya Pharmaceuticals Limited alone accounts for about 60% of APIs manufactured locally.

According to IQVIA, a US-based healthcare data science company, the country's pharmaceutical market surpassed Tk27,000 crore in 2020 with an annual growth of more than 10%. Bangladeshi companies also exported medicines worth around Tk1,500 crore in FY21. However, the country's top 10 companies sell about 71% of total medicines.

Link to comment
Share on other sites

  • 3 weeks later...
  • Elite Members


TBS Report

21 October, 2021, 09:20 pm

Last modified: 21 October, 2021, 09:23 pm

Square Pharmaceuticals’ annual profit grows by 19.38%

60% cash dividend recommended for 2020-21



Square Pharma maintained an average of 18.4 percent annual profit growth over the last seven years/Photo: Courtesy


Square Pharmaceuticals Ltd posted Tk1,594 crore in annual profit for the 2020-21 fiscal year, which is 19.38% higher compared to the previous year.

The profit growth boosted the top pharmaceutical company's earnings per share to Tk17.99 for the year, up from the previous year's Tk15.07.

The profit figures include that of its subsidiary companies. But the individual companies also posted growth in profits on a standalone basis.

Square Company Secretary Khandaker Habibuzzaman declined to comment beyond the disclosures after the board meeting.

However, one of his colleagues told The Business Standard that the company secured double digit revenue growth in the 2020-21 fiscal year, both on a standalone and consolidated basis.  

At the end of June this year, Square Pharma and its subsidiaries' combined net asset value per share stood at Tk102.54.

Square Pharmaceuticals board of directors recommended a 60% cash dividend for its shareholders, which would cost the company less than half of its annual profit.

Its board of directors also approved a Tk300 crore investment plan for BMRE (balancing, modernising, rehabilitation and expansion), buying new capital machinery and land for future expansion.

In its upcoming annual general meeting scheduled to be held on 15 December virtually, shareholders would consider the dividend plan and other agenda. Record date to identify shareholders is fixed on 22 November.

Square Pharmaceuticals had been waiting to begin manufacturing in its newly built Kenyan plant in August this year.

The company official who talked to The Business Standard seeking anonymity said, Due to the pandemic situation the commencement of operation abroad was delayed and he is expecting to begin production in the African plant at the end of this year.

The offshore plant is set to help the company diversify its supply chain and mitigate any impact of Bangladesh's LDC graduation a decade later.

Launched in 1958, Square Pharmaceuticals emerged as the industry leader in the mid-1980s and still holds the crown with around 17% market share.

The company got listed on the local bourse in 1995. Square Pharma shares closed 1.1% higher at Tk233.8 in the Dhaka Stock Exchange on Thursday.

The pharma market of the country is growing by 15% every year, according to the Bangladesh Association of Pharmaceutical Industries. The market is expected to grow four times to Tk1 lakh crore by 2030.


Link to comment
Share on other sites

  • Elite Members


Bangavax animal trial ends, found to be 100pc effective

Staff Correspondent

 22nd October, 2021 07:21:49 PM

Globe Biotech Limited (GBL) has completed the preclinical or animal trials of its homegrown coronavirus vaccine 'Bangavax' on Thursday.

The GBL conducted the trial on monkeys to meet the condition set by Bangladesh Medical Research Council (BMRC). The trial was completed on October 21.

The Globe Biotech authority claimed that the vaccine was found to be hundred per cent effective during the animal trials.
“During the animal trial of the Bangavax vaccine on monkeys, we have found that it has created sufficient anti-body and hundred per cent effective against all 11 coronavirus variants including the Delta one,” a senior manager of Globe Biotech Limited Dr Mohammad Mohiuddin told the Daily Sun. 

Based on the successful trials, company officials said, the local drug firm had approached the BMRC for ethical clearance before the human trials.

But the council approved clinical trials of Bangavax under the condition that "before starting any human trial, the vaccine producer will require to conduct an animal trial on monkeys or chimpanzees. Later, the GBL started animal trials of Bangavax on monkeys on August 1st in line with BMRC's condition, the company sources said.

They will now submit their clinical trial protocol to the BMRC next week to get approval for carrying out the human trial, they said. The company is planning to conduct the human trials from November.

Bangavax sought ethical approval from the BMRC for human trials of the antidotes on January 17 this year.

The BMRC on February 9 this year asked for some documents and the company submitted those on February 17 and received conditional approval in June.

Bangladeshi company Globe Biotech has received approval from the Directorate General of Drug Administration (DGDA) for manufacturing its vaccine for a clinical trial. The company was granted permission on 28 December last year, sources said.

Link to comment
Share on other sites

  • Elite Members


Rafiqul Islam & Tawsia Tajmim

20 October, 2021, 12:00 pm

Last modified: 20 October, 2021, 12:57 pm

Covid vaccine to be produced locally with a US formula

Vaccine production might start within next six months




  • The vaccine will be produced by state-owned Essential Drugs
  • Vaccine production might start within next six months
  • MoU will be signed with Dyadic International over transfer of raw materials and technology for producing vaccine
  • Technical committee on vaccine production has recommended allowing Dyadic to conduct clinical trials in the country
  • Appointments of consultant and scientist are in process

The government is planning to produce a coronavirus vaccine in the country through transfer of technology, using the formula invented by the US-based company Dyadic International.

Necessary steps are being taken to produce this vaccine at Essential Drugs Company Limited (EDCL), a state-owned drug manufacturing company in Gopalganj.

Initiatives are underway for a memorandum of understanding (MoU) to be signed in order to come by Dyadic's formula and technology, to set up vaccine plants in steel structures and to expedite the process of land acquisition.

If everything goes according to plan, the country might start producing protein vaccines within the next six months.

Professor ABM Khurshid Alam, convener of the Technical Committee on Vaccine Production and Director General of the Directorate General of Health Services (DGHS) told The Business Standard, "Negotiations are underway with the American company Dyadic. If they agree to transfer the technology, the vaccine will be produced in the country. If not, the vaccine will be brought in bulk and finished here."

The US biotechnology firm Dyadic International has already joined the race to produce Covid-19 vaccines in Africa, the least-vaccinated continent.

The company announced in July this year a technology transfer and licensing deal with South Africa's Rubic Consortium. Permission will be sought for the Covid-19 vaccine trial this year, according to a Bloomberg report.

Essential Drugs Company has meanwhile held several meetings with Dyadic International.

The government initially bought the Oxford University-developed AstraZeneca vaccine, which was supposed to be obtained from the Serum Institute of India. But, after supplying several consignments, India stopped exporting the vaccine due to increased corona infections within its territory. Then the Bangladesh government bought Pfizer, Moderna and Sinopharm vaccines from alternative sources.

An MoU will be signed with Dyadic over the transfer of raw materials and technology for producing vaccines in the country. A draft MoU has already been prepared. The MoU will be signed after getting government approval.

Professor Dr Ehsanul Kabir Jaglul, managing director of Essential Drugs Company Limited, said, "Dyadic International wants to sign an MoU. It will be signed after getting permission from the committee formed by the health ministry. Work on the signing of the MoU is in progress. If it is not signed, there is a risk that they will go elsewhere."

In addition to Dyadic, discussions are underway to produce protein vaccine invented by Russia's Sputnik-V and Oxford University, according to a meeting of the Parliamentary Standing Committee on Health and Family Welfare held on 13 October.

At the meeting, it was recommended that necessary steps be taken for the rapid production of vaccines in the country.

The meeting was informed that on the advice of experts, the main equipment for making corona vaccine will be imported from Europe, America and Japan while other equipment will be imported from various Asian countries, including China, South Korea and Taiwan.

An estimated cost relating to the imports has also been set by contacting various foreign equipment manufacturing and supplier organisations.

Technical committee on vaccine production and its recommendations

The government formed a nine-member Covid-19 Resistant Vaccine Production Technical Committee on 12 July this year, to make recommendations to the government by reviewing proposals and taking steps to produce effective and safe vaccines.

After holding five meetings since its formation, the committee put forward various recommendations for vaccine production.

According to committee sources, the technical committee has recommended that trials be allowed in the country to determine the efficacy and side effects of the vaccine invented by Dyadic International since Dyadic invented the formula but could not complete the trial. If the trial is allowed on the condition that the vaccine will be produced in Bangladesh, it can be produced as soon as possible. The committee recommended allowing the trial because formulas of the corona vaccines invented so far are not easily available.

Committee sources said there is also a shortage of raw materials of vaccine due to the widespread global demand for the corona vaccine. However, there will not be any shortage of raw materials for the production of Dyadic protein vaccines.

Dr Abdur Rahman, a member of the technical committee and dean of the Faculty of Pharmacy of Dhaka University, told TBS that it has been recommended that Dyadic be allowed to conduct clinical trials in the country; in return it will assist in setting up a vaccine plant and provide vaccine formula.

He said, "If this is done, we will get the vaccine formula in a short time and they will also get an advantage. The protein vaccine has a big advantage as there will be no shortage of raw materials for it. However, there is a shortage of raw materials for other vaccines due to the global demand."

Infrastructure development of Essential Drugs 

Although the government has taken the initiative to produce vaccines by the state-owned Essential Drugs Company, it does not have adequate and necessary infrastructure.

It was established in 1983 with the main objective of setting up an advanced pharmaceuticals industry in the country to produce medicines.

But this outdated pharmaceutical company does not have the necessary equipment and modern laboratory to produce corona vaccines. It is not possible to produce corona vaccines with its existing infrastructure.

However, the government's emphasis on vaccine production has removed the complexity of infrastructure development.

As the construction of a concrete building is time consuming, it has been decided to construct the building within a steel structure.

For the building eight acres of land have been acquired next to Essential Drugs Company. The steel structure will be built on the land to accommodate the necessary labs and equipment for vaccine production.

As per recommendations of experts, the vaccine will be stored in a cold room and cool room of the manufacturing plant at a temperature of 2-8 degrees centigrade.

Professor ABM Khurshid Alam said, "Ninety percent of the land has been acquired for the construction of the vaccine plant and the remaining 10% will be acquired this month."

"A steel structure will be built there to go into production as soon as possible. The appointments of a consultant and a scientist are in the process," he added. 

Link to comment
Share on other sites

  • 1 month later...
  • Elite Members


TBS Report

28 November, 2021, 08:50 pm

Last modified: 28 November, 2021, 08:52 pm

Beacon Pharma’s profit up on sales growth

In the last fiscal year that ended on 30 June, its revenue was Tk712 crore, which was Tk559 crore in the previous year


Beacon Pharmaceuticals Limited posted a 27% growth in revenue in fiscal 2020-2021 owing to an increase in demand for Covid-related products.

In the last fiscal year that ended on 30 June, its revenue was Tk712 crore, which was Tk559 crore in the previous year.

Its net profit stood at Tk86.39 crore, which was Tk38.07 crore the previous year.

At a board meeting on Sunday, the company recommended a 15% cash dividend for its shareholders for FY21.

In the previous fiscal year, it had recommended a 6% cash dividend for its shareholders.

The company has scheduled an AGM for 29 December 2021 and the record date for the AGM will be 20 November.

Khalilur Rahman, company secretary of Beacon Pharmaceuticals, said Covid-19 products are the main drivers of sales. During the year, it had demand both locally and internationally.

"We have made a higher profit amid the pandemic especially in the third quarter," he added.

The company has reported a profit of Tk260.12 crore in the third quarter, Tk218.36 crore in Q2 and Tk155 crore in Q1 this year.

Beacon is a very popular name in the country's pharmaceutical industry due to its high-quality anticancer drugs, cardiovascular drugs, gastrointestinal medicines, antibiotics, anti-coagulants, protein supplements, muscle relaxants, antihistamine, analgesics, and NSAIDs.

Beacon Pharma, incorporated in 2001 as a private limited company, was listed on local stock exchanges in 2010.

Till 31 October 2021, sponsors and directors jointly held 30%, institutions 34.01% and general public 35.99% shares in the company.

The last trading share price of the company at the Dhaka Stock Exchange was Tk227.70 on Sunday.

Link to comment
Share on other sites

  • 1 month later...
  • Elite Members


টিবিএস রিপোর্ট

30 December, 2021, 05:20 pm

Last modified: 30 December, 2021, 06:00 pm

কোভিড চিকিৎসার বড়ি বেক্সোভিড নিয়ে আসছে বেক্সিমকো

ফাইজারের মুখে খাওয়ার বড়ি প্যাক্সলোভিড-এর জেনেরিক সংস্করণ বাজারে আনবে বেক্সিমকো।



করোনা চিকিৎসায় ফাইজারের মুখে খাওয়ার বড়ি প্যাক্সলোভিড-এর জেনেরিক সংস্করণ (ব্র্যান্ড নাম ভিন্ন হলেও মূল পেটেন্টকৃত ওষুধের উপাদান দিয়ে তৈরি) বাজারে আনার ঘোষণা দিয়েছে বেক্সিমকো ফার্মাসিউটিক্যালস লিমিটেড। আজ বৃহস্পতিবার এ ঘোষণা দেওয়া হয়।

প্রতিষ্ঠানটি বেক্সোভিড নামে এই ওষুধ বাজারজাত করবে।

আজ ওষুধ প্রশাসন অধিদপ্তর (ডিজিডিএ) ১২ বছর বা তার বেশি বয়সি শিশুসহ প্রাপ্তবয়স্কদের হালকা থেকে মাঝারি করোনা রোগীদের চিকিৎসার জন্য মুখে খাওয়ার এই ওষুধের জরুরি ব্যবহারের অনুমোদন দিয়েছে।

এর আগে ২২ ডিসেম্বর ইউএস ফুড অ্যান্ড ড্রাগ অ্যাডমিনিস্ট্রেশন (এফডিএ) করোনা চিকিৎসার জন্য প্রথম মুখে খাওয়ার ওষুধ হিসেবে প্যাক্সলোভিডের অনুমোদন দেয়। 

নতুন এই ওষুধ ঝুঁকিতে থাকা প্রাপ্তবয়স্ক কোভিড রোগীদের মৃত্যু বা হাসপাতালে ভর্তি হওয়ার ঝুঁকি ৯০ পর্যন্ত কমিয়ে আনে বলে ক্লিনিকাল ট্রায়ালে প্রমাণিত হয়েছে। এছাড়াও করোনার নতুন ধরন ওমিক্রনের বিরুদ্ধেও বড়িটি কার্যকর প্রমাণিত হয়েছে।

বেক্সোভিড সম্পর্কে বেক্সিমকো ফার্মাসিউটিক্যালসের ব্যবস্থাপনা পরিচালক নাজমুল হাসান বলেন, মহামারির বিরুদ্ধে চলমান লড়াইয়ে শক্তিশালী অস্ত্র হওয়ার সম্ভাবনা আছে বেক্সোভিডের।

Link to comment
Share on other sites

  • 3 weeks later...
  • Elite Members


টিবিএস রিপোর্ট

19 January, 2022, 05:45 pm

Last modified: 19 January, 2022, 05:59 pm

ফাইজারের কোভিড প্রতিরোধী পিল বাজারে আনলো ইনসেপ্টা

ওষুধটি জুপিটাভির ব্র্যান্ড নামে বাজারজাতকরণ করা হবে বলে আজ বুধবার (১৯ জানুয়ারি) এক সংবাদ বিজ্ঞপ্তিতে জানানো হয়।



কোভিড-১৯ চিকিৎসায় মার্কিন যুক্তরাষ্ট্রের ফাইজার ইঙ্কের আবিষ্কৃত মুখে খাওয়ার অ্যান্টিভাইরাল বড়ি প্যাক্সলোভিড বাজারে আনার ঘোষণা দিয়েছে দেশীয় প্রতিষ্ঠান ইনসেপ্টা ফার্মাসিউটিক্যালস।

ওষুধটি জুপিটাভির ব্র্যান্ড নামে বাজারজাতকরণ করা হবে বলে আজ বুধবার (১৯ জানুয়ারি) এক সংবাদ বিজ্ঞপ্তিতে জানানো হয়।

ওষুধ প্রশাসন অধিদপ্তর (ডিজিডিএ) করোনাভাইরাসের মৃদু থেকে মাঝারি সংক্রমণে পিলটির জরুরী ব্যবহারের অনুমতি দিয়েছে। ১২ বছরের বেশি বয়সী শিশু থেকে প্রাপ্তবয়স্ক রোগীরা চিকিৎসকের ব্যবস্থাপত্র অনুসারে ওষুধটি খেতে পারবে।

এর আগে গত ২২ ডিসেম্বর মার্কিন খাদ্য ও ওষুধ প্রশাসন (এফডিএ) পিলটির জরুরী অনুমোদন দেয়। এটাই ছিল কোভিড-১৯ প্রতিরোধী কোনো সেবনযোগ্য ওষুধ অনুমোদনের প্রথম দৃষ্টান্ত।

মানব ট্রায়ালে অ্যান্টিভাইরাল পিলটি কোভিড-১৯ রোগে আক্রান্তদের হাসপাতালে ভর্তি হওয়ার মতো গুরুতর অসুস্থতা ও মৃত্যু রোধে ৯০ শতাংশ কার্যকারিতা দেখিয়েছে। গবেষণাগারে করা সাম্প্রতিক পরীক্ষার তথ্য বলছে, ওষুধটি অতি-সংক্রামক ওমিক্রন ভেরিয়েন্টের বিরুদ্ধেও কার্যকর।

নিরমাটরেলভির ও রিটোনাভির ট্যাবলেটের সাথে একসাথে প্যাকেটজাত করে ওষুধটি বাজারে আনা হয়েছে।

সার্স কোভ-২ ভাইরাসের এনজাইমকে আক্রমণ করে নিরমাটরেলভির ভাইরাসের বংশবিস্তার বন্ধ করে। আর রিটোনাভির নিরমাটরেলভিরের প্রভাবকে দীর্ঘমেয়াদি করে।  

রোগীর দেহে কোভিড-১৯ এর লক্ষণ দেখা দেওয়ার পর এবং শনাক্ত হওয়ার পাঁচদিনের মধ্যে চিকিৎসকের পরামর্শ অনুসারে জুপিটাভির সেবন করা যাবে।  

এর আগে গেল ৩০ ডিসেম্বর দেশের দুটি শীর্ষ ফার্মাসিউটিক্যাল কোম্পানি বেক্সিমকো ও এসকেএফ পৃথকভাবে প্যাক্সলোভিড বাজারজাতকরণ উদ্বোধন করে। বেক্সিমকো এটি বেক্সোভিড নামে বাজারে এনেছে, আর এসকেএফ এনেছে প্যাক্সোভির নামে। 

Link to comment
Share on other sites

  • Elite Members


TBS Report

20 January, 2022, 02:40 pm

Last modified: 20 January, 2022, 06:05 pm

Beximco Pharma gets license for oral anti-Covid drug

The company is expected to start domestic distribution and export from the end of 2022



Beximco Pharmaceuticals Limited has become the first Bangladeshi company to get permission to produce "molnupiravir," an oral drug for the treatment of Covid-19.

The United Nations-backed Medicines Patent Pool (MPP) granted a sub-license to Beximco Pharma for the local production of the oral drug originally developed by MSD, a trade name of Merck and Co Inc.

The partnership with Beximco was announced after the MPP expanded its network of partnered generic manufacturers, said a press release on Thursday.

The sub-license agreement is a result of the voluntary licensing agreement signed by the MPP and MSD in October 2021 to facilitate affordable global access for molnupiravir, which MSD is developing in partnership with Ridgeback Biotherapeutics.

Under this agreement, MPP may sub-license the production of the drug to global generic drug manufacturers to ensure a steady supply in different regions of the world. 

Molnupiravir is an oral antiviral to treat symptomatic Covid-19, which received conditional marketing authorisation in the UK from the UK Medicines and Healthcare Regulatory Agency on 4 November and received emergency use authorisation in the US from the US Food and Drug Administration on 23 December last year.

Beximco Pharma will manufacture molnupiravir in Bangladesh and is expected to start domestic distribution and export from the end of 2022, following successful technology transfer and manufacturing regulatory approvals under the license from MPP.

The company will continue to sell its own generic version of molnupiravir (Emorivir), as announced on 9 November 2021, under the World Trade Organization's Least Developed Country (LDC) waiver in the meantime.


Link to comment
Share on other sites

  • 4 months later...
  • Elite Members

The first ever penfill manufacturing plant in Bangladesh!

The state-of-the-art Novo Nordisk Penfill Insulin Manufacturing site was inaugurated last week at Gazipur Tongi. Transcom owned - Eskayef Pharmaceuticals Ltd set up the plant in its Tongi Production site with the technical collaboration from Novo Nordisk. The facility is expected to go into production by 2023 which will ensure an uninterrupted supply of human & modern insulin for diabetic patients in Bangladesh.



Link to comment
Share on other sites

  • Elite Members

The oncology manufacturing facility of Eskayef Pharmaceuticals Ltd. , one of the finest medicine manufacturing companies in Bangladesh, has obtained the approval of European Union Goods Manufacturing Practice (EU GMP) for maintaining its standard in production of oncology drugs.

This approval has huge global influence and is regarded as a ‘passport’ to enter the global market.

The oncology unit of SKF Pharmaceuticals is situated at Rupganj, Narayanganj. Both the injection and oral medicines of SKF have the EU GMP approval. This suggests SKF could maintain the European standard in commercial production and standard maintenance of oncology medicines.

National Institute of Cancer Research & Hospital - NICRH Director, Professor Qazi Mushtaq Hussain said, " It is indeed a matter of honor for Bangladesh as a local company has won this acknowledgement for manufacturing cancer drugs. This will dispel all the doubts, if there is any, about our quality of medicines and treatment. This is comforting for the people and medical treatment."

SKF authorities said SKF Oncology is the first in Bangladesh to use isolator technology to ensure safety of the medicine at its every step of production. The company imports quality raw materials from the European countries. The state-of-the-art oncology manufacturing facility of SKF Pharmaceuticals was opened in 2018 with the technical help of Europe-based Telstar Life Science Solutions, t.

SKF Oncology is currently manufacturing medicines of various types of cancer including breast cancer, blood cancer, lung cancer, colorectal cancer, bladder cancer, renal cancer, hepatocellular cancer and head-neck cancer.


Link to comment
Share on other sites

  • 1 month later...
  • Elite Members


Delay in building vaccine plant is unacceptable

Red tape must not be allowed to stall such an important project

Thu Jul 14, 2022 05:46 PM Last update on: Thu Jul 14, 2022 05:54 PM

It is disconcerting that a highly important drug manufacturing project is finding it difficult to take off because of bureaucratic meddling. A report by this daily reveals that the work of the planned vaccine manufacturing and research plant in Gopalganj remains stalled for over one year now. The government took the decision to set up the plant in July last year, following rising demands for Covid-19 vaccines. According to health experts, despite the countrywide vaccine drive that has since inoculated a large percentage of the population, we need continuous vaccination all year round because of quick mutations of the virus, which is still very much a force to be reckoned with.

Thus, the urgency of producing vaccines besides procuring them from abroad has been felt by experts, and accordingly, the prime minister gave her consent with the advice to expedite work. But in reality, no progress – apart from a few meetings between officials of the Essential Drugs Company Ltd, Asian Development Bank, and the finance ministry – could be made so far.

Looking at the sorry state of what was deemed a top-priority project for the government, we wonder why it was allowed to flounder even before it could take off. Surprisingly, even the parliamentary committee on the health ministry could not make things move faster, thanks to the all-encompassing influence of red tape. A member of the committee lamented that because of the government's complex way of working, the project has seen little progress since inauguration. He further raised caution that the vaccine plant may not be able to go into production any time soon. The question is: Why this state of affairs? What could be more crucial from a public health perspective other than developing vaccine self-sufficiency?

Unfortunately, a good number of government projects in the past have suffered similar delays as well as cost overruns mostly because of mismanagement and bureaucratic botch-ups. Since vaccines are urgently needed to increase the immunity of citizens, and heavy reliance on vaccine imports makes no sense at this juncture, we hope directors of the vaccine plant project will take the matter with the highest urgency and implement it without further delay.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...